Pharmacological Management of Gastrointestinal Neuroendocrine Tumors
dc.contributor.advisor | Pórszász, Róbert | |
dc.contributor.advisordept | Debreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet | hu_HU |
dc.contributor.author | Lawrence, Janet | |
dc.contributor.department | DE--Általános Orvostudományi Kar | hu_HU |
dc.contributor.opponent | Drimba, László | |
dc.contributor.opponent | Megyeri, Attila | |
dc.contributor.opponentdept | Kenézy Kórház, Központi Aneszteziológiai és Intezív Terápiás Osztály | hu_HU |
dc.contributor.opponentdept | Debreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet | hu_HU |
dc.date.accessioned | 2022-08-15T11:22:09Z | |
dc.date.available | 2022-08-15T11:22:09Z | |
dc.date.created | 2022-03-21 | |
dc.description.abstract | Gastrointestinal Neuroendocrine tumors are a rare diverse group of tumors arising from the diffuse neuroendocrine system. In recent times the incidence and prevalence of these tumors have increased which has led to further investigations on the treatment of these tumors. Somatostatin analogues are still the pillar of pharmacological therapy. It is used with a combination of other agents .These agents help with symptom relief and tumor progression free survival. There is still room for improvement for therapies to achieve overall better survival | hu_HU |
dc.description.corrector | hbk | |
dc.description.course | általános orvos | hu_HU |
dc.description.courselang | angol | hu_HU |
dc.description.degree | egységes, osztatlan | hu_HU |
dc.format.extent | 45 | hu_HU |
dc.identifier.uri | http://hdl.handle.net/2437/336477 | |
dc.language.iso | en | hu_HU |
dc.subject | Gastrointestinal Neuroendocrine tumors | hu_HU |
dc.subject | Somatostatin analogues | hu_HU |
dc.subject.dspace | DEENK Témalista::Orvostudomány | hu_HU |
dc.title | Pharmacological Management of Gastrointestinal Neuroendocrine Tumors | hu_HU |